Genzyme 4Q Revenues: $1.0 billion (+21%) 4Q Earnings: $78.9 million (loss of $268.2 million 4Q06) FY Revenues: $3.8 billion (+20%) FY Earnings: $480.2 million (loss of $16.8 million FY06) Comments: Revenue growth was driven by strong sales of its newest drug, Myozyme, with sales up 107% in the quarter to $62 million. For the year sales reached $201 million compared to the first-year sales of $59 million. 4Q Fabrazyme sales were $114 million (+18%) and FY sales were up 18% to $424 million. C...